Skip to main content

Table 1 Tumor types and chemotherapy regimens used by cohort for participants in this study

From: Safety and feasibility of fasting in combination with platinum-based chemotherapy

Cancer type Chemotherapy regimen Disease state
24 h cohort
 Urothelial Gemcitabine + Cisplatin Metastatic
 Urothelial Gemcitabine + Cisplatin Adjuvant
 NSCLC Gemcitabine + Cisplatin Metastatic
 Urothelial Gemcitabine + Cisplatin Neoadjuvant
 Ovarian Carboplatin + Paclitaxel Adjuvant
 Uterine Carboplatin + nab-Paclitaxel Metastatic
48 h cohort
 Ovarian Carboplatin + Paclitaxel Adjuvant
 Breast TCH Adjuvant
 Breast TCH Adjuvant
 Breast TCH Adjuvant
 Urothelial Gemcitabine + Cisplatin Neoadjuvant
 Breast TCH Adjuvant
 Ovarian Carboplatin + Paclitaxel Metastatic
72 h cohort
 Ovarian Carboplatin + Paclitaxel Metastatic
 Urotheliala Gemcitabine + Cisplatin Neoadjuvant
 Uterine Carboplatin + Paclitaxel Adjuvant
 Breast TCH Neoadjuvant
 Urothelial Gemcitabine + Cisplatin Neoadjuvant
 Ovarian Carboplatin + Paclitaxel Adjuvant
 Ovarian Carboplatin + Paclitaxel Metastatic
  1. TCH Docetaxel, carboplatin, trastuzumab
  2. aThis patient was ineligible due to BMI 20.1 (original protocol required ≥20.5 but the protocol was subsequently amended to allow patients with normal BMI ≥18.5 given a lack of weight loss observed in the first 2 cohorts) and the data were included from 2 successful fasting cycles